Beyond Air Inc (XAIR)
Beyond Air, Inc. is a commercial-stage healthcare company listed on the NASDAQ under the symbol XAIR. The company develops medical device and biopharmaceutical products centered on its LungFit nitric oxide generation and delivery platform. Its commercial product, LungFit PH, is used for persistent pulmonary hypertension of the newborn. Beyond Air is also advancing LungFit PRO for hospitalized patients with viral lung infections, including community-acquired pneumonia, COVID-19, and bronchiolitis, as well as LungFit GO for use in the home treatment of nontuberculous mycobacterial infection. In addition, the company is developing UNO for solid and cutaneous tumors and a selective nNOS inhibitor for neurological conditions and autism spectrum disorder. Beyond Air was founded in 2011, is based in Garden City, New York, and operated under the name AIT Therapeutics, Inc. until 2019.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-XAIR
|
$4.14
|
29.3% Upside
|
Undervalued
|
$20
|
525.0% Upside
|
Bargain
|
Fair
|
0.0%
|
November 16, 2026
|
1.5x
|
0.4x
|
3.15 M
|
17.709 M
|
85.7%
|
88.7%
|
-16.4
|
58.5%
|
